[1] Brar G, Tsukamoto H. Alcoholic and non-alcoholic steato-hepatitis: global perspective and emerging science. J Gastroenterol, 2019,54:218-225.
[2] Bataller R, Arteel GE, Moreno C, et al. Alcohol-related liver disease: Time for action. J Hepatol, 2019,70:221-222.
[3] 王炳元.重视酒精性肝炎的临床研究.临床肝胆病杂志, 2019, 35:469-471.
[4] Hydes T, Gilmore W, Sheron N, et al. Treating alcohol-related liver disease from a public health perspective. J Hepatol, 2019,70:223-236.
[5] Gustot T, Jalan R. Acute-on-chronic liver failure in patients with alcohol-related liver disease. J Hepatol, 2019,70:319-327.
[6] Lackner C, Tiniakos D. Fibrosis and alcohol-related liver disease. J Hepatol, 2019,70:294-304.
[7] Gao B, Ahmad MF, Nagy LE, et al. Inflammatory pathways in alcoholic steatohepatitis. J Hepatol, 2019,70:249-259.
[8] Singal AK, Shah VH. Current trials and novel therapeutic targets for alcoholic hepatitis. J Hepatol, 2019,70:305-313.
[9] Im GY, Cameron AM, Lucey MR. Liver transplantation for alcoholic hepatitis. J Hepatol, 2019,70:328-334.
[10] Mathurin P, Thursz M. Endpoints and patient stratification in clinical trials for alcoholic hepatitis. J Hepatol, 2019,70:314-318. |
